
    
      Metastasis lesion of stage IV NSCLC will be treated with a SBRT of 50Gy/4-10F from day 1 to
      day 14 in one cycle. Subcutaneous injection of human recombined granulocyte-macrophage colony
      stimulating factor (125ug/mÂ² per day) will be executed from day 1 to day 14 in this cycle.
      Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a
      consecutive cycle.Thymosin Alpha 1(1.6mg Biw) will be Subcutaneous injection from the fist
      week to the 12th weeks, Efficacy evaluation, especially abscopal effect evaluation, will be
      conducted at the end of therapy and every month after that. Adverse events will be recorded
      according to NCI-CTC version 4.03.
    
  